Ocular Therapeutix, Inc. announced that the first three subjects have been screened and received their firstaflibercept injection in the Phase 3 SOL-1 clinical trial of AXPAXLI?? (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The Company previously announced FDA agreement on its Special Protocol Assessment (SPA) Agreement Modification on January 25th.

Dr. Hu is an active principal investigator of innovative technologies for the treatment of macular degeneration, diabetic retinopathy and retinal vascular disorders, having participated in over 40 clinical trials over the past 10 years. Ocular Therapeutix's first commercial drug product, DEXTENZA®?, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain followingophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular TherapeutIX's earlier stage development assets include: AXPAXLI (axitinib Intravitreal implant), currently in a pivotal Phase 3 trial for the treatment of wet AMD and a Phase 1 clinical trial for the treatment of diabetic retinopathy; PAXTRAVA??

(travoprost intracameral implant, also known as OT X-TIC), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) For the short-term treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA or any product or product candidate that receives regulatory approval; the ability to retain regulatory approval of DEXTENZA or any products or product candidate that receives regulatory approved; the ability to retain regulatory approved of DEXTENZA or Any product or product candidate that receives Regulatory approval; the ability to maintain and the sufficiency of product, procedure and any other reimbursement codes for DEXTENZA; the initiation, design, timing, conduct and outcomes of clinical trials, including the SOL-1 trial; the risk that the FDA will not agree with the Company's interpretation of the written agreement under the SPA; the risk that even though the FDA has agreed with the overall design of the SOL-1 trial, the FDA may not agree that the data generated by the SOL-1 trial supports potential marketing approval; uncertainty as to whether the data from earlier clinical trials will be predictive of the data of later clinical trials, particularly later clinical trials, particularly laterclinical trials, particularly later clinical trials that have a different design or utilize a different formulation than the earlier trials; availability of data from clinical trials and expectations for regulatory submissions and expectations for regulatory submissions and approval.